Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Pacira BioSciencesViela BioAlkermesALX OncologyFibroGen
SymbolNASDAQ:PCRXNASDAQ:VIENASDAQ:ALKSNASDAQ:ALXONASDAQ:FGEN
Price Information
Current Price$68.25$53.01$19.02$63.77$18.57
52 Week RangeBuyHoldHoldBuyHold
MarketRank™
Overall Score2.00.81.21.91.8
Analysis Score3.31.11.03.54.1
Community Score2.91.22.83.82.5
Dividend Score0.00.00.00.00.0
Ownership Score0.00.81.71.71.7
Earnings & Valuation Score3.80.60.60.60.6
Analyst Ratings
Consensus RecommendationBuyHoldHoldBuyHold
Consensus Price Target$77.50$57.00$20.86$90.67$45.83
% Upside from Price Target13.55% upside7.53% upside9.66% upside42.18% upside146.81% upside
Trade Information
Market Cap$2.99 billion$2.91 billion$3.03 billion$2.56 billion$1.70 billion
Beta1.270.431.25N/A1.59
Average Volume491,1511,065,0581,290,751244,0051,384,721
Sales & Book Value
Annual Revenue$421.03 million$50 million$1.17 billionN/A$256.58 million
Price / Sales7.1158.262.59N/A6.63
Cashflow$1.60 per shareN/A$0.51 per shareN/AN/A
Price / Cash42.56N/A37.52N/AN/A
Book Value$8.51 per share$7.14 per share$6.89 per shareN/A$6.14 per share
Price / Book8.027.422.76N/A3.02
Profitability
Net Income$-11,020,000.00$-86,430,000.00$-196,620,000.00N/A$-76,970,000.00
EPS$0.86($7.02)$0.07N/A($0.89)
Trailing P/E Ratio24.03N/AN/A0.00N/A
Forward P/E Ratio23.70N/A271.71N/AN/A
P/E Growth0.82N/A12.74N/AN/A
Net Margins29.95%N/A-6.28%N/A-191.78%
Return on Equity (ROE)10.71%-33.97%9.35%N/A-48.19%
Return on Assets (ROA)4.88%-31.49%5.50%N/A-27.72%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.78%N/A0.25%N/AN/A
Current Ratio7.63%19.51%2.71%N/A6.23%
Quick Ratio6.84%19.49%2.39%N/A6.13%
Ownership Information
Institutional Ownership PercentageN/A46.98%97.30%73.45%75.05%
Insider Ownership Percentage5.80%31.50%4.49%N/A3.39%
Miscellaneous
Employees6061662,24517599
Shares Outstanding43.86 million54.95 million159.24 million40.13 million91.56 million
Next Earnings Date5/6/2021 (Estimated)5/12/2021 (Estimated)5/5/2021 (Estimated)6/17/2021 (Estimated)5/6/2021 (Estimated)
OptionableOptionableNot OptionableOptionableNot OptionableOptionable
SourceHeadline
Glancy Prongay & Murray LLP, a National Class Action Law Firm, Continues Investigation of FibroGen Inc. (FGEN) on Behalf of Investors - GlobeNewswireGlancy Prongay & Murray LLP, a National Class Action Law Firm, Continues Investigation of FibroGen Inc. (FGEN) on Behalf of Investors - GlobeNewswire
globenewswire.com - April 10 at 6:26 AM
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against FibroGen, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm - PRNewswireONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against FibroGen, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm - PRNewswire
prnewswire.com - April 9 at 10:42 PM
Fibrogen Deadline AlertFibrogen Deadline Alert
finance.yahoo.com - April 9 at 10:42 PM
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against FibroGen, Inc. and Encourages Investors with Losses of $100,000 to Contact the FirmONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against FibroGen, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm
finance.yahoo.com - April 9 at 5:41 PM
Do Traders Think FibroGen Inc (FGEN) Can Turn Around Friday? - InvestorsObserverDo Traders Think FibroGen Inc (FGEN) Can Turn Around Friday? - InvestorsObserver
investorsobserver.com - April 9 at 12:41 PM
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages FibroGen (FGEN) Investors with Losses to Contact Its Attorneys Now, Company Admits to Manipulating Data for Anemia Drug - Yahoo FinanceHAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages FibroGen (FGEN) Investors with Losses to Contact Its Attorneys Now, Company Admits to Manipulating Data for Anemia Drug - Yahoo Finance
finance.yahoo.com - April 9 at 12:41 PM
Is Fibrogen Still a Buy Following Data Analysis Faux Pas? Analyst Weighs In - Yahoo FinanceIs Fibrogen Still a Buy Following Data Analysis Faux Pas? Analyst Weighs In - Yahoo Finance
finance.yahoo.com - April 9 at 12:41 PM
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of FibroGen Inc. (FGEN) on Behalf of Investors - Yahoo FinanceINVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of FibroGen Inc. (FGEN) on Behalf of Investors - Yahoo Finance
finance.yahoo.com - April 9 at 7:25 AM
FibroGen, Inc. Investors: Company Investigated by the Portnoy Law Firm - Yahoo FinanceFibroGen, Inc. Investors: Company Investigated by the Portnoy Law Firm - Yahoo Finance
finance.yahoo.com - April 9 at 7:25 AM
FIBROGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating FibroGen, Inc. on Behalf of FibroGen Stockholders and Encourages Investors to Contact the Firm - Business WireFIBROGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating FibroGen, Inc. on Behalf of FibroGen Stockholders and Encourages Investors to Contact the Firm - Business Wire
businesswire.com - April 8 at 10:47 PM
Is Fibrogen Still a Buy Following Data Analysis Faux Pas? Analyst Weighs InIs Fibrogen Still a Buy Following Data Analysis Faux Pas? Analyst Weighs In
finance.yahoo.com - April 8 at 10:47 PM
FIBROGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating FibroGen, Inc. on Behalf of FibroGen Stockholders and Encourages Investors to Contact the FirmFIBROGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating FibroGen, Inc. on Behalf of FibroGen Stockholders and Encourages Investors to Contact the Firm
finance.yahoo.com - April 8 at 10:47 PM
Scott+Scott Attorneys at Law LLP Announces Investigation into FibroGen, Inc. (FGEN) - Business WireScott+Scott Attorneys at Law LLP Announces Investigation into FibroGen, Inc. (FGEN) - Business Wire
businesswire.com - April 8 at 5:42 PM
FibroGen, Inc. Investors: Company Investigated by the Portnoy Law Firm - GlobeNewswireFibroGen, Inc. Investors: Company Investigated by the Portnoy Law Firm - GlobeNewswire
globenewswire.com - April 8 at 5:42 PM
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages FibroGen (FGEN) Investors with Losses to Contact Its Attorneys Now, Company Admits to Manipulating Data for Anemia Drug - PRNewswireHAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages FibroGen (FGEN) Investors with Losses to Contact Its Attorneys Now, Company Admits to Manipulating Data for Anemia Drug - PRNewswire
prnewswire.com - April 8 at 12:41 PM
FibroGen (NASDAQ:FGEN) Sees Large Volume IncreaseFibroGen (NASDAQ:FGEN) Sees Large Volume Increase
americanbankingnews.com - April 8 at 12:16 PM
Ademi LLP Investigates Claims of Securities Fraud against FibroGen Inc. - PRNewswireAdemi LLP Investigates Claims of Securities Fraud against FibroGen Inc. - PRNewswire
prnewswire.com - April 8 at 7:41 AM
Ademi LLP Investigates Claims of Securities Fraud against FibroGen Inc.Ademi LLP Investigates Claims of Securities Fraud against FibroGen Inc.
finance.yahoo.com - April 8 at 7:41 AM
FibroGen Provides Additional Information on Roxadustat - Yahoo FinanceFibroGen Provides Additional Information on Roxadustat - Yahoo Finance
finance.yahoo.com - April 8 at 12:44 AM
UPDATED: FibroGen shares take a beating as CEO reveals safety data manipulation for its blockbuster contender roxadustat - Endpoints NewsUPDATED: FibroGen shares take a beating as CEO reveals safety data manipulation for its blockbuster contender roxadustat - Endpoints News
endpts.com - April 8 at 12:44 AM
FibroGen admits misleading safety data for anemia drug, dimming prospects - BioPharma DiveFibroGen admits misleading safety data for anemia drug, dimming prospects - BioPharma Dive
biopharmadive.com - April 8 at 12:44 AM
Ahead of FDA meeting, FibroGen stock dips on questions about data analysis - San Francisco Business Times - San Francisco Business TimesAhead of FDA meeting, FibroGen stock dips on questions about data analysis - San Francisco Business Times - San Francisco Business Times
bizjournals.com - April 8 at 12:44 AM
Fibrogen stretches the bounds of credibility - VantageFibrogen stretches the bounds of credibility - Vantage
evaluate.com - April 8 at 12:44 AM
FibroGen admits to messing with roxadustat safety data, upending hopes for the AZ-partnered anemia drug - FiercePharmaFibroGen admits to messing with roxadustat safety data, upending hopes for the AZ-partnered anemia drug - FiercePharma
fiercepharma.com - April 8 at 12:44 AM
FibroGen Stock Falls Following Disclosure of a "Major Oops" - BarronsFibroGen Stock Falls Following Disclosure of a "Major 'Oops'" - Barron's
barrons.com - April 8 at 12:44 AM
FibroGen (NASDAQ:FGEN) Lifted to Neutral at JPMorgan Chase & Co.FibroGen (NASDAQ:FGEN) Lifted to Neutral at JPMorgan Chase & Co.
marketbeat.com - April 7 at 10:12 AM
FibroGen (NASDAQ:FGEN) Raised to "Buy" at Bank of AmericaFibroGen (NASDAQ:FGEN) Raised to "Buy" at Bank of America
marketbeat.com - March 31 at 7:42 AM
DateCompanyBrokerageAction
4/9/2021Pacira BioSciencesBerenberg BankInitiated Coverage
3/8/2021Pacira BioSciencesHC WainwrightBoost Price Target
2/26/2021Pacira BioSciencesBarclaysBoost Price Target
2/11/2021Pacira BioSciencesNorthland SecuritiesDowngrade
1/21/2021Pacira BioSciencesSVB LeerinkDowngrade
1/20/2021Pacira BioSciencesPiper SandlerBoost Price Target
1/8/2021Pacira BioSciencesNeedham & Company LLCBoost Price Target
1/6/2021Pacira BioSciencesRoyal Bank of CanadaBoost Price Target
11/2/2020Pacira BioSciencesWedbushLower Price Target
9/30/2020Pacira BioSciencesJefferies Financial GroupBoost Price Target
8/14/2020Pacira BioSciencesTruistBoost Price Target
2/8/2021Viela BioGuggenheimDowngrade
8/13/2020Viela BioStifel NicolausReiterated Rating
7/15/2020Viela BioThe Goldman Sachs GroupUpgrade
6/3/2020Viela BioCowenReiterated Rating
5/14/2020Viela BioMorgan StanleyBoost Price Target
1/7/2021AlkermesMizuhoBoost Price Target
10/7/2020AlkermesJPMorgan Chase & Co.Reiterated Rating
9/30/2020AlkermesBank of AmericaLower Price Target
1/31/2020AlkermesWolfe ResearchUpgrade
4/6/2021ALX OncologyUBS GroupInitiated Coverage
2/11/2021ALX OncologyCredit Suisse GroupBoost Price Target
1/6/2021ALX OncologyCantor FitzgeraldBoost Price Target
9/30/2020ALX OncologyLifesci CapitalReiterated Rating
4/7/2021FibroGenRaymond JamesReiterated Rating
3/19/2020FibroGenCitigroupLower Price Target
(Data available from 4/11/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.